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HIGHLIGHTS
Manganese texaphyrin binds to
Ab constructs (i.e., monomer,
fibrils, and aggregates)
MRI studies demonstrate the
utility of metallotexaphyrins for
detecting Ab aggregates
Antioxidant assays show potential
utility of MMn for treating CNS
neurodegenerationSessler et al. have studied manganese(II) texaphyrin as a catalytic
metalloantioxidant theranostic agent for the detection of Ab aggregates. A series
of in vitro and in vivo analyses allowed for the inference that metallotexaphyrins
could be used for MRI-based detection of Ab biomarkers. In vitro and cellular-
based assays coupled with mechanistic analysis demonstrated an efficacious
protective effect against oxidative and nitrative damage. The present results could
thus guide future efforts in developing new theranostic modalities for use in
neurodegenerative disease.Brewster et al., Chem 6, 1–22
March 12, 2020ª 2019 The Author(s). Published
by Elsevier Inc.
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Neurodegenerative disease is
correlated with aberrant oxidation
and nitration of small-molecule
neurotransmitters, proteins, DNA,
and cellular membrane
components. Cellular damage
enhanced by these modifications
propagates disease progression,
leading to death. Effective tools
that enable insight into the
complex etiology of CNS diseases
could allow researchers to find a
cure. Part of this effort is focused
on developing imaging
modalities that can assist in
understanding these diseases.
Here, we demonstrate a new
theranostic strategy that shows
promise in addressing the
oxidative and nitrative
malfunctions considered causal in
disease progression. The
approach detailed in this report
also allows the MRI of aggregated
Ab, which could lead to
improvements in disease
diagnosis. The present work is
thus expected to set the stage for
the mechanistic-based design of
theranostics, useful in
understanding and treating
neurodegeneration.SUMMARY
The complex etiology of neurodegeneration continues to stifle efforts to
develop effective therapeutics. New agents elucidating key pathways causing
neurodegeneration might serve to increase our understanding and potentially
lead to improved treatments. Here, we demonstrate that a water-soluble man-
ganese(II) texaphyrin (MMn) is a suitable magnetic resonance imaging (MRI)
contrast agent for detecting larger amyloid beta constructs. The imaging poten-
tial of MMn was inferred on the basis of in vitro studies and in vivo detection in
Alzheimer’s disease C. elegansmodels via MRI and ICP-MS. In vitro antioxidant-
and cellular-based assays provide support for the notion that this porphyrin
analog shows promise as a therapeutic agent able to mitigate the oxidative
and nitrative toxic effects considered causal in neurodegeneration. The present
report marks the first elaboration of an MRI-active metalloantioxidant that con-
fers diagnostic and therapeutic benefit in Alzheimer’s disease models without
conjugation of a radioisotope, targeting moiety, or therapeutic payload.
INTRODUCTION
Many seminal advances in physiology and medicine have been made by hewing to a
reductionism-centered mantra wherein discrete biological functions are attributed
to individual processes. However, an increased understanding of the complex inter-
actions between cellular components (e.g., DNA, RNA, proteins, and small mole-
cules) is leading to a more nuanced view.1 For instance, it is now recognized that
a number of key biological effects arise from interaction webs involving multiple
biochemical processes operating within a scale-free network.2 Such an appreciation
is considered particularly relevant to the problem of understanding the central ner-
vous system (CNS) and diseases that affect it.3
Among CNS disorders, neurodegeneration is particularly insidious. It defines a se-
ries of complex disease states that lead to death. Current therapies, at best, amelio-
rate the symptoms with limited long-term benefit to patients or relief to caregivers.4
The complex etiology of neurodegeneration derives from known and unknown initi-
ators operating simultaneously within a feedback loop that is thought to exacerbate
downstream toxicity.5 In particular, Alzheimer’s disease (AD) has been postulated to
arise from abnormal protein deposits, excitotoxicity, disruption of metal-ion homeo-
stasis, reduction in endogenous antioxidants, and neuroinflammation, among other
hypotheses.6 Most, if not all, of these putative malfunctions are correlated with an
increase in reactive oxygen species (ROS) and reactive nitrogen species (RNS).7Chem 6, 1–22, March 12, 2020 ª 2019 The Author(s). Published by Elsevier Inc.
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Study on Alzheimer’s Disease, Chem (2019), https://doi.org/10.1016/j.chempr.2019.12.016Both ROS and RNS are thought to disrupt standard cellular processes giving rise to
dysfunction and neuronal cell death.8 Here, we report that a first-generation water-
soluble manganese(II) texaphyrin (MMn) displays cell permeability and allows for the
detection of larger order amyloid beta (Ab) constructs (i.e., aggregates) by means of
magnetic resonance imaging (MRI). Inductively coupled plasma-mass spectrometry
(ICP-MS) and MRI analyses of in vivo (C. elegans) AD models provided further sup-
port for this notion. Based on in vitro mechanistic studies, this texaphyrin system
also mitigates the oxidative and nitrative toxicity effects considered causal in CNS
neurodegeneration. It thus shows promise as a new tool that may aid in understand-
ing, imaging, and treating neurodegenerative disease.
Deciphering the precise biochemical deviations from a normal network that are
associated with CNS neurodegeneration is considered key to finding a cure.9–11
Within this paradigm, significant efforts have focused on developing accurate bio-
markers through cerebrospinal fluid (CSF) protein analysis and positron emission to-
mography (PET) imaging.12,13 These test methods have proven useful in furthering
our understanding of disease progression; however, they can be invasive and expen-
sive. MRI has emerged as a potential complement to CSF and PET analyses.14
Recent efforts have also focused on the use of theranostics, wherein a fluorophore,
MRI-active metal ion, or radioisotope is conjugated with a therapeutic function-
ality.15 Many of these conjugates have relied on either Pittsburgh compound B
(PiB)- or curcumin-based systems for imaging combined with an Ab aggregation in-
hibitor to provide therapeutic efficacy. MR-based imaging systems for the study of
neurodegeneration have generally relied on Gd-DOTA or related aminopolycarbox-
ylate ligands conjugated to antibodies or other targeting moieties. Cell and blood-
brain-barrier permeability remains a major issue in such agents and could represent
a serious impediment to regulatory approval and ultimate clinical utility.16
Expanded porphyrins, porphyrin-like systems containing a larger internal cavity than
natural tetrapyrrolic congeners, have received considerable attention in recent
years.17 One such system is texaphyrin, a penta-aza Schiff base macrocycle.18
Compared with porphyrins, texaphyrins contain an approximately 20% larger core
and display a unique electronic structure. These systems also exhibit efficacious bio-
logical activity with cell permeability and potential in humanmedicine.19 In fact, spe-
cific water-soluble gadolinium(III) and lutetium(III) texaphyrin derivatives, known as
MGd and MLu, respectively, were explored early on as potential therapeutics; the
pro-oxidative MGd was studied through phase III clinical trials as a radiosensitizer,
and MLu was studied through phase I clinical trials for photoangioplasty.20–22
Notably, MGd demonstrated a high maximum tolerated dose (22.3 mg kg1) and
a median half-life of 7.4 h and could be detected within brain metastases
even 14 h after administration, as determined by MRI. Recently, dual-modal MGd-
platinum(IV) conjugates have shown promise as potential cancer drug leads.23
Mn(III) porphyrin and corrole metalloantioxidants have demonstrated an efficacious
therapeutic effect that is thought to be mediated via decomposition of peroxynitrite
(ONOO) and, in some instances, superoxide and hydrogen peroxide (H2O2)
(Figure 1).24 In particular, AEOL-10150, an octaethyl imidazolium Mn(III) porphyrin,
has shown broad-spectrum superoxide dismutase (SOD)-like activity in animal
models of amyotrophic lateral sclerosis (ALS), idiopathic pulmonary fibrosis, and
nerve agent exposure (Figure 1).25 AEOL-10150 has also successfully completed a
phase I clinical trial in ALS and healthy patients.26 Recent studies involving a wa-
ter-soluble Fe(III)-corrole have also demonstrated utility in attenuating Ab-Cu(II)-
mediated ROS.23 However, the precise therapeutic mechanism remains recondite2 Chem 6, 1–22, March 12, 2020
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Figure 1. Chemical Structures of Representative Porphyrinoids
As discussed in the text proper, hemin catalyzes oxidative and nitrative damage. Manganese(II) texaphyrin (MMn) is the subject of this study.
Manganese(III) tetramethylpyridinium porphyrin (MnTMPyP) is a manganese porphyrin metalloantioxidant. AEOL-10150 has successfully completed a
phase I trial in ALS and healthy patients and has shown efficacy in animal models for radiation- and nerve-agent-induced toxicity. Axial ligands are
omitted for clarity. See main text for further discussion of these agents.
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formations (e.g., peroxidase activity).27,28 Limited cellular uptake and acute toxicity
in the case of polycationic pyridinium Mn porphyrins are also an issue.
The interaction of hemin and other water-soluble phthalocyanines, corroles, and
porphyrins with Ab has been noted.29–32 We thus envisaged that coupling the Ab-re-
cognition properties of metalloporphyrins with the biological activity of metallotex-
aphyrins would allow for MRI recognition of Ab species with attendant utility as a
potential metalloantioxidant therapeutic (Figure 2). As detailed further below, we
have found that metallotexaphyrins, in particular MMn, interact with amyloid con-
structs, as inferred from ultraviolet-visible (UV-vis), fluorescence, and circular dichro-
ism (CD) spectroscopies, as well as MRI studies. The protective effect of MMn
against oxidative and nitrative damage was also demonstrated by means of
in vitro studies with Ab peptides and serotonin as model protein and small-molecule
neurotransmitter substrates, respectively, and in cell culture with Neuro-2A cells.
The protective and oxidative properties of Mn(III) tetramethylpyridinium porphyrin
(MnTMPyP), a gold-standard Mn porphyrin metalloantioxidant, were also studied
in vitro and in Neuro-2A cell cultures. These studies revealed rapid decomposition
of MnTMPyP under oxidative conditions consistent with a sacrificial substrate-based
antioxidant mechanism. Studies involving C. elegans models were also carried out
with MMn and provide support for the notion that this first-generation metallotexa-
phyrin may be administered and detected in amyloid plaque-bearing AD models. It
and related systems could thus have a role to play in the study and eventual manage-
ment of neurodegenerative disease.RESULTS AND DISCUSSION
Spectroscopic Analyses of Metallotexaphyrin-Ab Interactions
Initial studies of the interactions between MMn and Ab40 involved UV-vis spectro-
scopic analyses. This technique was chosen because changes in the intensity or
wavelength (energy) of the Soret band (p-to-p* transition) of metalloporphyrinoids
are often indicative of axial coordination.33 Reduction in the molar absorptivity can
also arise from coordination within a peptide or protein tertiary structure.34 MMn,
like other porphyrinoids, is intensely colored. It is dark green in most media in which
it is soluble and characterized by strong Soret- and Q-like bands at lmax = 459 and
726 nm, respectively, in pH 7.4 phosphate-buffered saline (PBS). The addition of
monomeric Ab40 (5 mM, 1 equiv) into a PBS solution of MMn (5 mM) resulted in a
decrease in spectral intensity for the Soret-like band (ε= 73,700/ 62,500M1cm1;Chem 6, 1–22, March 12, 2020 3
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Figure 2. The Aggregation State of Ab Peptides as a Function of Incubation Time
The three Ab40 constructs utilized in this study: (left) freshly dissolved peptide is predominantly monomeric in solution, (middle) soluble oligomeric
species (partially aggregated) are produced after incubation in solution, and (right) fibrils and fully soluble and insoluble aggregates are formed after
prolonged incubation. Ab16 remains monomeric in solution.
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molar absorptivity (ε = 72,450 M1cm1 at 20 equiv) with a slight spectral shift in the
absorption maximum also being seen (lmax = 462 nm; Figure 3). UV-vis spectral an-
alyses provided support for the conclusion that the Ab40 peptide (ε= 1,480M
1cm1
at 280 nm) remains soluble upon addition to MMn. Specifically, no sign of precipita-
tion was observed, even when tested at high concentrations of Ab40 (i.e., 100 mM;
Figure S5). A titration of MMn with human serum albumin (HSA) showed a similar
reduction in absorbance intensity but yielded no shift in the Soret or Q bands (Fig-
ure S6). Considered in tandem, the changes to the UV-vis spectral features of MMn
observed in the presence of monomeric Ab40 are consistent with the coordination of
one or more axial ligands to the texaphyrin metal center. However, the potential for-
mation of a soluble, higher-order Ab40 species (e.g., a dimeric-MMn complex) in
solution cannot be excluded. Under these same conditions, a titration of MnTMPyP,
a commercially available porphyrin considered as a gold-standard metalloantioxi-
dant, with Ab40 yielded no change in the observed spectrum (Figure S7). Similar
spectral changes to the texaphyrin profile were, however, seen when Ab40 was
added to MGd (Figure S7). The marked differences between MMn (and MGd) and
MnTMPyP when exposed to Ab40 are believed to arise from differences in the struc-
ture and charge of the overall complex. MnTMPyP is decorated with four pyridinium
functionalities positioned perpendicular to the porphyrin core, whereas MMn is
formally monocationic, planar, and functionalized with flexible pendant substituents
capable of hydrogen bonding.
Since Ab16 remains monomeric in solution and conserves the relevant amino acids
considered responsible for Ab coordination chemistry, an analogous titration was
carried out between MMn and Ab16 (0–80 equiv) in an effort to differentiate between
the effects of aggregation (hydrophobic interactions) and axial coordination on the
observed UV-vis spectral changes. UV-vis spectra of MMn recorded as it was
exposed to Ab16 were characterized by an initial reduction in spectral intensity,
just as was observed in the corresponding Ab40 studies. This decrease was followed
by a corresponding increase in spectral intensity. In analogy to what was seen in the
case of monomeric Ab40, approximately 17.5 equiv of Ab16 (as opposed to 15 equiv4 Chem 6, 1–22, March 12, 2020
Figure 3. Interaction of MMn with Monomeric and Aggregated Ab40
(A) Titration with MMn (5 mM) andmonomeric Ab40 with 0 (black), 1 (light blue), and 20 (purple) equiv
and (B) photos of aggregated Ab40 (100 mM; aged 2 months) in the absence and presence of MMn
(100 mM) in PBS and after washing with PBS. The pellet shown in the right-most image was obtained
by centrifugation and is in methanol.
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discernible increase or change in the Soret band (lmax) was observed (i.e., upon
addition of >20 equiv Ab16; cf. Figure S8). The spectral changes induced by Ab16
andmonomeric Ab40 were thus attributed to axial ligand binding rather than seques-
tration by oligomeric or aggregated peptide species.
MMn was also titrated with Ab40 (0–20 equiv) that was pre-incubated for 14 days in
PBS at room temperature. This pre-incubated material is believed to contain higher-
order oligomeric species (i.e., partial aggregates containing b sheets; cf. Figure 2).
Treating MMn with oligomeric Ab40 (1 equiv) engenders a decrease in the UV-vis
spectral intensity (ε = 73,700/ ε = 45,600 M1cm1), a finding attributed to both
axial ligand binding and incorporation of MMn within the aggregate structure.
Upon adding additional oligomeric Ab40 (up to 20 equiv), an increase in spectral in-
tensity (ε = 50,000 M1cm1) and a bathochromic shift in the Soret band maximum
(to lmax = 462 nm) were observed (Figure S9). Analyses of the relative spectral
intensity of the Soret and Q bands (ratio of absorbance at 459 and 726 nm) revealed
a minute change in this ratio for aggregated (3.39:1) and monomeric (3.43:1) forms
of Ab40. This was taken as further support for the suggestion that the UV-vis spectral
changes seen for MMn upon exposure to Ab40 originate from both axial coordination
to the Mn(II) center and texaphyrin encapsulation within Ab40 oligomers, fibrils, and
aggregates.
To gain insights into the interactions between MMn and fully aggregated Ab spe-
cies, we mixed constructs composed of Ab40 that had been aged for 2 months
(a highly aggregated form) with MMn (100 mM, 1 equiv). After centrifugation, a
green pellet was obtained. Even after washing and vortex mixing with deionized
(DI) water (three times) and resuspension in methanol, the pellet remained green
(Figure 3). A time-dependent UV-vis analysis of the spectral changes seen for
MMn when exposed to this same aggregated Ab40 species was carried
out by following the decrease in the absorbance intensity of the Soret band
(l = 459 nm) as a function of time. Upon addition, an immediate decrease was
observed. A further reduction in the absorbance intensity was then seen over the
ensuing 30 min (Figure S10).Chem 6, 1–22, March 12, 2020 5
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in an effort to discriminate between selectivity for Ab40 versus general biomolecule
interactions. The first addition of Ab40 (25 mM) to a preformed MMn (5 mM)-HSA
(5.5 mM) complex induced a slight decrease in the absorption intensity of the Soret
(5.8%) and Q (6.3%) bands. Subsequent addition of Ab40 (25 mM) again resulted in a
further decrease in the absorption intensity of the Soret (4.6%; 10.4% total) and Q
(6.8%; 13.1% total) bands with concomitant bathochromic shifts in the Soret band
from 459 to 460 nm andQ band from 726 to 728 nm (Figure S11). Increasing the con-
centration of Ab40 (125 mM) and HSA (600 mM) yielded a green pellet by centrifuga-
tion in the presence and absence of HSA after the induction of Ab fibrillization
through storage at 4C for 48 h (Figure S12).35 However, the MMn-Ab40 pellet
formed in the presence of both HSA and Ab40 was smaller (ca. 0.2 cm) than that
formed when MMn was treated with just Ab40 (ca. 0.35 cm). No pellet was formed
from MMn in the absence of Ab40.
Further attempts to probe the interactions between MMn and oligomeric Ab were
made with an Ab40 (aged 1 week) Thioflavin T (ThT) assay.
36 The benzothiazole scaf-
fold for ThT is a recognized binding agent for Ab sequences conserved amongmany
PET agents (e.g., the FDA-approved Vizamyl [flutemetamol (18F)]) and theranostics
used in AD research.37 New small molecules with binding affinities similar to that
of ThT could thus prove useful for clinical application.30 As important, the ThT assay
can provide evidence of binding within Ab40 because of the well-defined ThT-Ab40
emission profile.36 Changes in the observed fluorescence correspond to ThT
displacement or structural modification of the Ab40 aggregate. To exploit this assay,
we added MMn (1 to 10 equiv) in aliquots to Ab40 (aged 1 week) containing
ThT (ThT-Ab40 constructs). These additions engendered a series of changes,
including spectral shifts and an overall decrease in the intensity (Figure S13).
Through-space quenching of bound or free MMn, as a result of the matched absorp-
tion spectrum of MMn and emission profile of ThT-Ab40 constructs, accounts
for some of the initial decrease (Figures S14 and S15). Continued modification of
the fluorescence profile was seen upon the addition of each aliquot of MMn, a
finding consistent with the presence of multiple binding sites within the Ab40 aggre-
gate. The observed modifications to the fluorescence profile are thus largely
attributed MMn-induced structural reorganization that is triggered by binding to
aggregated Ab40.
We carried out high-performance liquid chromatography (HPLC) analyses in an
effort to elucidate further the interactions between ThT (100 mM), MMn (100 mM),
or MLu (100 mM) and 2-month-aged Ab40 aggregates (100 mM) (Figure S16). After in-
cubation at room temperature for 24 h, 77% ThT remained in the supernatant, as
determined by integration against a ThT control (100 mM). Co-incubation with
MMn or MLu (24 h at room temperature) effected little significant displacement
given that 66.7% ThT and 7% MMn remained in the supernatant, as determined
by HPLC analysis using ThT and MMn standards. A similar HPLC study using the
diamagnetic MLu revealed that only 5.4% of the MLu remained in the supernatant
(Figure S17). NMR spectroscopic experiments carried out with preformed ThT-Ab40
samples (ThT [0.47 mM] and Ab40 [0.40 mM]) in conjunction with MLu (0.49 mM)
revealed signs of ThT displacement after incubation for 24 h at room temperature
(Figures S18 and S19). Additional NMR spectroscopic analyses using monomeric
Ab40 (1.9 mM) andMLu (2.1 mM) in DMSO-d6 revealed changes to the proton signals
ascribed to MLu and the Ab40 peptide. The most notable difference after the
addition of Ab40 was a change in the chemical shift for the axial acetate anions
originally bound to MLu; this is as would be expected under a scenario where the6 Chem 6, 1–22, March 12, 2020
Figure 4. Modification of Aggregated Ab40 by MMn as Monitored by CD Spectroscopy and SEM
Analyses
CD spectra (left) of aggregated (aged for 30 days) Ab40 (40 mM) were recorded before and after the
addition of MMn (20 mM) at t = 0, 7, and 24 h. SEM photographs (right) of (A) Ab40 aggregate, (B) an
Ab40 aggregate incubated with MMn for 24 h, and (C) monomeric Ab40 are shown.
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taken as evidence that metallotexaphyrins bind well to aggregated Ab, most likely
through multiple binding sites, even if the specifics of the interaction are not fully
elucidated.
Clinical trials aimed at the modification of higher-order oligomeric and aggregated
Ab have yet to yield viable therapeutics.11 An ability to produce and detect such
modifications remains of interest in terms of assessing the potential impact of other
treatment modalities. CD studies designed to assess the ability of MMn (20 mM) to
interact with and modify the aggregate structure of Ab (20 mM, aged 30 days)
revealed no marked differences in the CD spectrum immediately after mixing.
However, noticeable changes relative to the initial CD spectrum were observed
7 and 24 h after mixing (Figure 4). In particular, the intensity of the negative CD
band at 220 nm seen for aggregated Ab40 underwent a decrease in intensity of
approximately 35% at 24 h with an attendant shift in the wavelength minimum to
ca. 218 nm. These data are interpreted in terms of a reduction in the percentage
of b sheet composition and modification of the overall aggregate structure.38 Con-
trol studies monitoring the progression over 24 h with aged Ab40 in the absence of
MMn revealed no significant change (Figure 4).
Scanning electron microscopy (SEM) provided further support for the proposed
modification of the Ab40 aggregate structure (Figure 4). The Ab40 aggregate
(40 mM) utilized for CD experiments (aged 30 days plus 24 h) was characterized byChem 6, 1–22, March 12, 2020 7
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30 days) incubated with MMn (20 mM) for 24 h displayed features at 3 mm more
closely resembling those of an amorphous species (Figure 4B). Freshly prepared
Ab40 showed no discrete features even when magnified to 2 mm (Figure 4C).
In Vitro and In Vivo MRI
As a general rule, paramagnetic Gd(III) and high-spin Mn(II) ions enhance the relax-
ation rates of nearby proton nuclei. Not surprisingly, these cations have been
incorporated intoMRI contrast agents (CAs).39 Gd-based systems remain the current
clinical standard. However, Mn-based CAs have recently been explored as surro-
gates for Gd systems and as new intramolecular MRI probes.40,41 Detailed MRI
studies on MGd have previously been reported,42 including human trials where ev-
idence of tumor-targeted imaging via enhanced drug uptake within tumor cells was
obtained.18,19 However, the congeneric Mn(II) systemMMn has yet to be the subject
of extensive study in the context of MRI.43,44
MRI CAs are generally described by relaxivities, r1 and r2, in mM
1 s1. These param-
eters are defined as the concentration-dependent enhancement of longitudinal (R1)
and transverse (R2) water proton relaxation rates, each given in s
1, respectively. At
the field used in this study (7 T), MMn displayed exceptional relaxivities in non-coor-
dinating buffers (7 T, HEPES [pH 7.4], 25C; MMn r1 = 4.59G 0.12 mM
1 s1 and r2 =
32.2G 0.3 mM1 s1; MGd r1 = 16.0G 0.5 mM
1 s1 and r2 = 23.5G 0.6 mM
1 s1;
Gd-DTPA r1 = 4.93 G 0.06 mM
1 s1 and r2 = 6.65 G 0.02 mM
1 s1) with well-
behaved (i.e., linear) relaxation rates as a function of concentration. The longitudinal
relaxivity of MMn in the coordinating buffer (i.e., PBS) was slightly reduced at r1 =
1.2 mM1 s1. Current CAs are known to be limited at these higher fields and previ-
ous examples of Ab-binding MRI agents have, in general, been investigated at a
lower magnetic-field strength.39,40,45 The ability of MMn to engender high relaxiv-
ities at a higher field could make such agents of clinical interest in the context of
neurodegenerative disease. Studies with Ab peptides were carried out as a first
step toward exploring this potential.
Changes in the relaxation rates (R1 and R2) after addition of monomeric and aggre-
gated Ab40 (70 mM) to solutions of MMn (70 or 140 mM) at 25C in PBS (pH 7.4) were
monitored at 7 T with a multi-spin multi-echo scanning sequence. Bovine serum al-
bumin (BSA, 70 mM) was used as a control biomolecule (Figure 5). All of the additives
tested gave rise to an increase in the longitudinal relaxation rates of MMn. Control
studies demonstrated that Ab40 alone displayed no significant effect on the relaxa-
tion rate of the buffer (R1 = 0.400G 0.005 s
1 versus the PBS control R1 = 0.398G
0.005 s1). Relative to the relaxation value generated by MMn alone, aggregated
Ab40 induced the largest increase in R1 (Figure 5A). The modest increase observed
for monomeric Ab40 and albumin coupled with the observed enhancement in the
R1 parameter in the case of aggregated Ab is taken as a further indication that
such agents could find utility in theMRI-based detection of Ab aggregate constructs.
Interestingly, with the fully aggregated Ab40, the R1 increase was substantially larger
for 2 equiv of MMn (ca. 62% versus MMn alone) than for 1:1 MMn/Ab40 (ca. 37%
versus MMn alone) (Figure S21). Considered in light of the ThT-Ab40 fluorescence
assay results described above, these data are taken as a further indication that
MMn binds to multiple sites within aggregated Ab40. The MRI properties of Gd(III)
texaphyrin (MGd, 70 mM) in the presence of aggregated Ab28 (500 mM) and BSA
(600 mM) were also monitored at 7 T with a multi-spin multi-echo scanning sequence
at 25C in PBS (pH 7.4). However, these studies failed to show selectivity or signifi-
cant changes in either R1 or R2 in either case (Figure S22).8 Chem 6, 1–22, March 12, 2020
Figure 5. In Vitro MRI Analyses of MMn with Various Ab40 Constructs
(A) The longitudinal relaxation rate (R1) of MMn (140 mM) with monomeric (0.5 equiv, 70 mM), partial
(1 week, 0.5 equiv, 70 mM), and aggregated (>2 months) Ab40 (0.5 equiv, 70 mM) in comparison with
MMn alone (140 mM) and in the presence of BSA (0.5 equiv, 70 mM). Dots represent individual
samples; the mean (red line) and 95% confidence level for the mean (light red) are also displayed.
Standard deviations are either indicated in blue or not shown if within the 95% confidence level.
(B) Phantom T1-weighted MRI images of 140 mM MMn were recorded in the presence of increasing
concentrations of Ab40 aggregate (0–70 mM) in PBS at 7 T and 25
C. Samples are normalized to MMn
alone, shown in the left-most box.
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remains difficult for most MRI CAs and often comes at the cost of desirable physico-
chemical properties (e.g., LogP and solubility).16,40,41 Cell-uptake studies using
MMn (30 mM), LogP 0.69, and the Neuro-2A cell line with a 9 h incubation period pro-
duced a green cell pellet with a 5.5-fold increase in the Mn content (2.2 ppb per
million cells) versus the no-drug control (0.4 ppb per million cells), as quantified
by ICP-MS analysis (Figure S23). MRI of the resultant cell pellet suspended in PBS
provided additional support for the proposed increase in uptake given that both
R1 (from 0.382 G 0.004 to 0.412 G 0.004 s
1) and R2 (from 2.43 G 0.03 to 2.71 G
0.03 s1) were enhanced in comparison with the no-MMn control.
In order to probe the possible utility of MMn for in vivo MRI-based detection of
neurodegenerative disease, we incubated an AD model of C. elegans (CL4176) ex-
pressing amyloid plaques in the presence of MMn (1 mL/100 mM).46 The resulting
MMn content, measured by MRI and ICP-MS, was compared to what was seen in
the case of the wild-type strain, N2. On the basis of reported drug absorption and
retention within C. elegans, we envisaged that MMn would interact and be retained
within the amyloid plaques, yielding higher MRI and ICP-MS signals than theChem 6, 1–22, March 12, 2020 9
Figure 6. ICP-MS and In Vivo MRI Analyses of MMn in C. elegans AD Models
Mn concentrations (A), as determined by ICP-MS, and (B) MRI analyses of MMn for pellets of wild-
type (N2) and AD model (CL4176) C. elegans with and without MMn. Pellets were standardized by
dissolving every 1 mg C. elegans in 100 mL HEPES and digesting in HNO3. n = 5–8 per sample, 2
replicates of each for ICP-MS measurements and n = 2–5 for MRI measurements. Dots represent
individual samples; the mean (red line) and 95% confidence level for the mean (light red) are shown.
Standard deviation (blue) is shown where larger than the 95% confidence level. *Two-sample t test
on ICP-MS variance between MMn-wild-type (WT) and -AD models; p = 0.00018.
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excretion cycles. Control experiments using E. coli OP50 with MMn and worms
without MMn were carried out concurrently with the experiments involving the N2
and CL4176 strains (Figure S24). MRI studies on the resulting pellets suspended in
HEPES buffer (10 mM [pH 7.4], 1 mg pellet per 100 mL HEPES) showed an enhanced
R1 signal in the CL4176 AD model (0.394G 0.012 s
1) when they were administered
MMn versus the N2 treated with MMn in an equivalent way (0.360 G 0.002 s1), as
well as no-MMn CL4176 (0.364G 0.003 s1), N2 (0.344G 0.003 s1), and E. coliwith
MMn control studies (0.333G 0.002 s1). A similar trend was also seen in the case of
the R2 with relevant values: CL4176 AD model with MMn (3.44 G 0.20 s
1), N2
with MMn (2.82 G 0.03 s1), no-drug CL4176 (3.14 G 0.02 s1), no-drug N2
(2.59 G 0.10 s1), and E. coli with MMn control (2.450 G 0.04 s1) (Figure S25).
A second batch displayed a similar trend (Figure S26).
As expected, both batches of C. elegans incubated with MMn showed higher Mn
signal in the N2 and CL4176 strains than did the same strain without the texaphyrin
(Figure 6). ICP-MS analyses of pellet suspensions (1 mg C. elegans per 100 mL
HEPES) revealed Mn uptake values of 82 G 11 mM (SD) for the CL4176 AD model
and 48 G 11 mM for the wild-type N2 (Figure S27). The increased metal uptake in
the AD model is taken as evidence of the accumulation of MMn within the amyloid
plaque over multiple uptake-drug-excretion cycles.
In Vitro ROS and RNS Reactivity Studies
Nitrative and oxidative damage is prevalent in AD brains.48 Oxidized and nitrated
neurotransmitters, DNA bases, proteins, metalloenzymes, and cellular membrane
components are also correlated with disease progression. These chemical changes
are thought to alter up- and downstream biochemical processes via inactivation,10 Chem 6, 1–22, March 12, 2020
Figure 7. 1H NMR Spectroscopic Study of the Hemin-Mediated Oxidation of Serotonin
NMR yields were calculated by comparing the spectra of (A) serotonin (1 mM) in pH 7.4 PBS at 37C
in the presence of (B) hemin (15 mM) and an oxidative mixture containing H2O2 (1 mM) and sodium
ascorbate (40 mM), (C) an H2O2-ascorbate oxidative mixture plus MnTMPyP (120 mM), and (D) an
H2O2-ascorbate oxidative mixture plus MMn (120 mM) recorded after a reaction time of 120 min in
all cases.
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gestion that oxidation and nitration of the amyloid peptide and tau proteins leads to
enhanced cytotoxicity with attendant neuronal cell death.51,52 MMn is known to
display distinct redox behavior in comparison with its related Mn(III)porphyrin and
corrole congeners.53 Previous work on MMn has also illustrated the possibility of de-
activating ONOO catalytically in the presence of sodium ascorbate (NaAsc) with
attendant application in preventing formation of nitrotyrosine in ALS mice
models.54,55 The propensity of metallotexaphyrins to interact with Ab constructs
coupled with the unique redox capabilities of MMn led us to explore whether this
specific metallotexaphyrin could be used to mitigate the effects of hemin-mediated
oxidation and nitration and copper-mediated oxidation of small-molecule neuro-
transmitters and amyloid peptides. The pro-oxidative and protective (antioxidant)
activity of MnTMPyP has also previously been reported.24,56 It was thus studied for
comparative purposes.
Serotonin was used as the first test substrate. When hemin is activated in the pres-
ence of hydrogen peroxide, serotonin undergoes an oxidative transformation to
yield the neurotoxic 4,40-serotonin dimer (5,50-dihydroxy-4,40-bitryptamine
[DHBT]). The antioxidant (protective) effect of MMn was studied with serotonin
(1 mM) with hemin (15 mM) and an oxidative mixture consisting of hydrogen peroxide
(1 mM) and NaAsc (40 mM) in PBS (pH 7.4) at 37C for 2 h. By comparing the changes
observed in the corresponding 1H NMR spectra in D2O, we could compare the anti-
oxidant effect of MMn against that of MnTMPyP, a well-studied Mn(III)-porphyrin
metalloantioxidant, and the pro-oxidative hemin control (Figure 7). Under these con-
ditions, MMn proved the most protective, leaving behind 63% of unmodified sero-
tonin. In contrast, the hemin/H2O2/ascorbate and hemin/H2O2/ascorbate/
MnTMPyP mixtures showed a marked increase in serotonin oxidation with 36%Chem 6, 1–22, March 12, 2020 11
Figure 8. HPLC-MS Analyses of the Oxidative and Nitrative Modification of Ab16
(A) Ab16 incubated under hemin-nitration conditions using heme-H2O2-NaNO2 with varying
concentrations of MMn. Percent composition of Ab16 is shown in black and, as expected, increases
with the [MMn].
(B) The protective effect of MMn was also tested against heme-peroxynitrite-mediated
modification of Ab16 in comparison with MnTMPyP. Sodium ascorbate (NaAsc) was added to
regenerate the MMn catalyst under the reaction conditions. Reported values are averages with the
corresponding standard deviation as obtained from two independent measurements.
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(15 mM) and H2O2 (1 mM) without NaAsc revealed that MMn was protective, yielding
70% of unmodified serotonin versus 60% and 40% remaining for hemin/H2O2 and
hemin/H2O2/MnTMPyP, respectively (Figure S28). Additional NMR spectroscopic
experiments designed to evaluate the protective effect of MMn against Cu(II),
another metal ion considered relevant to oxidation in CNS disorders, were also car-
ried out (Figure S28). Qualitative 1H NMR spectroscopic analyses using Cu(II)Cl2
(100 mM), serotonin (1 mM), and H2O2 (1 mM) without and with MMn (120 mM) re-
vealed that prolonged incubation times and high concentrations of the metal salt
were necessary for producing low levels of oxidation. Shorter reaction times
and lower concentrations of Cu(II) led to no detectable oxidation, as inferred from
1H NMR spectral studies.
MMn also proved efficient at deactivating the oxidative modification of histidine
(H13-H14), nitration of tyrosine (Y10), and oxidative dimerization of tyrosine (Y10)
in Ab16 by the more reactive hemin, as determined by high-performance liquid
chromatography-tandem mass spectrometry (HPLC-MS/MS) analysis. The Ab16
sequence serves as a soluble surrogate for larger amyloid species or other proteins
that could suffer degradation when treated with the oxidative mixture of hemin-
hydrogen peroxide (15 mM-1 mM) or copper(II) (15, 60, or 150 mM) with hydrogen
peroxide (1 mM) or nitrative mixtures of hemin-hydrogen peroxide-sodium nitrite
(15 mM-1 mM-1 mM) and hemin-ONOO (15 mM-1 mM) at 37C in phosphate buffer
(pH 7.4, 5 mM). A range of reaction variables—such as the use of acidic pH thought
relevant to neurodegeneration,57 solution ionic strength (5 versus 50 mM), reaction
time (2–24 h), and the presence or absence of MnTMPyP, MGd, and curcumin—were
also studied in the context of hemin-mediated oxidation and nitration of Ab16 (Fig-
ures S29–S32). Within the range of a normal physiological pH of 7.4 in low-ionic-
strength 5 mM phosphate buffer, only 25.1% G 2.1% (SD) of the Ab16 remained in
the case of the additive-free control, composed of Ab16 (300 mM), hemin (15 mM),
H2O2 (1 mM), and NaNO2 (1 mM). MMn was found to militate against oxidation
and nitration of Ab16 with an IC50 = 4.22 mM and a maximal inhibition of 97.4% G
0.4% at 60 mMMMn under nitrative conditions (Figure 8A). A similar protective effect
by MMn was also seen under oxidative conditions of Ab16 (300 mM), hemin (15 mM),
H2O2 (1 mM), and MMn (30 mM), yielding 98%G 0.4% of unchanged Ab16. Control
experiments without MMn, with MGd, and with the sacrificial antioxidant curcumin12 Chem 6, 1–22, March 12, 2020
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2% (D =12.9%) of unchanged Ab16, respectively. At a more acidic pH of 6.3 and the
higher ionic strength (i.e., 50 mM phosphate buffer), under nitrative conditions, the
amount of remaining Ab16 (300 mM) decreased from 63.5% G 1.4% at pH 7.4 to
33.3% at pH 6.3 (heme-H2O2-NaNO2; 10 mM-1 mM-1 mM). However, the protective
effect of MMn (30 mM) was enhanced such that 98.8%G 0.6% of the Ab16 remained
intact. This increased benefit is believed to arise from deactivation rates that are
accelerated in more acidic media. The results of the Cu(II)-H2O2 experiments proved
difficult to quantify. This difficulty reflects the minimal oxidative reactivity of Cu(II) at
levels appropriate for HPLC-MS analysis (Figure S33). Under conditions analogous to
those tested in the case of hemin, Cu(II) (15 mM) with H2O2 (1 mM) incubated at 37C
for 2 h in phosphate buffer (pH 7.4, 5 mM) returned 96.9% G 1.7% of unchanged
Ab16. The addition of MMn (30 mM) to Ab16 (300 mM), Cu(II) (15 mM), and H2O2
(1 mM) yielded 98.7% G 0.4% unchanged Ab16.
It is worth stressing that although it promotes the oxidation of serotonin, the gold-
standard control system, MnTMPyP, was found to be protective against the oxida-
tion and nitration of Ab16. In particular, MnTMPyP showed an excellent protective
effect against oxidative modification by yielding 97.4% G 0.6% unmodified Ab16.
MnTMPyP also proved protective against nitrative modification by yielding
88.7% G 0.6% unmodified Ab16 (Figure S34). These are both similar to the values
observed for MMn (98% G 0.4% for oxidation and 91% G 0.1% for nitration). The
observed protective effect of MnTMPyP is thought to arise from rapid oxidative
degradation of hemin and MnTMPyP via the iron- and Mn-oxo porphyrin intermedi-
ates. This loss in complex arising from MnTMPyP serving as a sacrificial antioxidant
would, in turn, we propose, preclude extensive oxidation or nitration of this amyloid
peptide (i.e., Ab16) during the time course of the 2 h reactivity study. UV-vis analyses
provided further support for the notion that MnTMPyP (5 mM) serves as a sacrificial
substrate in the presence of hemin (15 mM) and H2O2 (1 mM) given that only 13%
MnTMPyP and 60% hemin remain after incubation for 10 min at 37C in phosphate
buffer (pH 7.4) (Figure S35). A control experiment with hemin alone under the same
conditions yielded 56% unmodified hemin.
Reactivity studies designed to test the protective effect against ONOO-mediated
damage of Ab16 were also carried out. Here, a mixture of hemin (15 mM), Ab16
(300 mM), and ONOO (1 mM) were incubated at 37C for 30 min in phosphate
buffer (5 mM, pH 7.4) and yielded 0.2% G 0.1% unmodified Ab16. In the presence
of MMn (30 mM) with NaAsc (500 mM) as the reductant, 82.6%G 3.7% of the original
Ab16 remained. Notably, in the presence of MnTMPyP and NaAsc, only 0.4% Ab16
was observed intact under otherwise identical conditions (Figure 8B). We attribute
this lack of protection for MnTMPyP to the rapid oxidative action of ONOO and for-
mation of an oxidative high-valent Mn- or Fe-oxo species that could oxidize Ab16
prior to decomposition.58 According to early mechanistic studies, such oxo species
are not thought to be produced when MMn is used to deactivate ONOO in the
presence of NaAsc.54 Control experiments with NaAsc (500 mM), MMn (30 mM) alone
(not containing a reductant to regenerate the active Mn(II) species), and MGd as a
texaphyrin control containing a non-redox-active metal conferred little protection,
such that 20.6% G 20.4%, 1.6% G 1.2%, and 1.6% G 0.2% Ab16 remained intact,
respectively (Figure S32).
UV-vis spectroscopic studies revealed that upon addition of MMn (1 equiv, 10 mM) to
the six-coordinate 2:1 low-spin Ab16-heme (200-10 mM) complex, formed by the
addition of an excess of Ab16 to hemin, a hypsochromic shift in the absorption ofChem 6, 1–22, March 12, 2020 13
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Scheme 1. Proposed Mechanism for the MMn-Based Deactivation of Hemin- and Peroxynitrite
(ONOO)-Mediated Oxidation and Nitration, as well as Oxidative Decomposition of Hydrogen
Peroxide (H2O2)
Redox cycle of Mn(II/III) texaphyrin. Compounds I and II are generated by the reaction of hemin with
H2O2. The Ab peptide and axial ligands are omitted for clarity.
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changes can be ascribed to two possible mechanisms. First, upon addition of MMn,
the reversion from 412 to 409 nm in the Soret band could reflect deconstruction of
the 2:1 heme-Ab16 construct to yield a mixed low- (2:1) and high-spin (1:1) Ab16-
heme species via MMn displacement of the heme bound to Ab16.
59 A separate
mechanism could also be operable wherein MMn co-binds within the 2:1 Ab16-
heme construct to distrupt the Ab axial coordination to hemin or modification of
the secondary coordination environment responsible for the enhanced peroxidase
activity. To such an extent that this latter rationale is correct, it would support a
mechanism where MMn-mediated protection results from a proximity effect, as
well as an attenuation of the heme peroxidase activity that is normally enhanced
upon coordination of hemin to amyloid peptides.59 Both proposed mechanisms
would be expected to induce changes to the UV-vis spectrum of the 2:1 hemin-
Ab16 complex.
A proposed mechanism for the deactivation of iron-oxo-mediated oxidation and
nitration is shown in Scheme 1. In briefl, the hemin-Ab complex is activated by
H2O2 or ONOO
 to yield a highly oxidative porphyrin p-radical cation/iron(IV)-
oxo species (compound I in Scheme 1A).60 The resultant species readily oxidizes
hydrogen peroxide or nitrite as well as tyrosine, histidine, or methionine residues
in Ab (producing compound II in Scheme 1). MMn could confer a protective effect
by reducing compound I and/or compound II, resulting in the formation of an
oxidizedMn(III) texaphyrin. In contrast to Mn peroxidase and certain model Mn com-
plexes, such as Mn(III)TMPyP (vide infra), the resulting oxidized Mn(III) texaphyrin
fails to carry out additional oxidative chemistry on the peptide or small redox-active
molecules. The oxidized Mn(III) texaphyrin can then be reduced by ascorbate or
oxidative decomposition of H2O2 to O2 and 2 H
+ (Figure S37).54 Support for this14 Chem 6, 1–22, March 12, 2020
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of Mn(III) texaphyrin (generated with ONOO) was observed after the addition of
10 equiv H2O2 within 3 min at room temperature in PBS (Figure S38). A control
experiment that involvedmonitoring the reduction of Mn(III) texaphyrin toMn(II) tex-
aphyrin without H2O2 yielded approximately 7% reduced Mn(III) after 20 min when
left open to air at room temperature. Under the reaction conditions containing a
large excess of H2O2 (1 mM) versus MMn (30 mM), it is expected that the H2O2 oxida-
tion mechanism will dominate the catalytic cycle to regenerate Mn(II) texaphyrin.
No oxidation of Mn(II) texaphyrin to the corresponding Mn(III) species was observed
with H2O2 alone (Figure S39).
As implied above, these proposed MMn-relevant mechanisms stand in contrast to
what is thought to occur with Mn(III)TMPyP. Under oxidizing conditions, such as
those employed in this study, the Mn(III) center of MnTMPyP is oxidized to give a
Mn(IV)-oxo species that promotes self-decomposition and substrate oxidation.
The mixed protective (antioxidant) and oxidative properties of MnTMPyP is thus
attributed to variations in the respective redox profile of MnTMPyP versus various
biological substrates.61 Indeed, in instances where the substrate is more prone to
oxidative modification (e.g., serotonin or methionine), a pro-oxidative-type mecha-
nism dominates.55 In cases where the substrate is less labile under oxidative condi-
tions (e.g., histidine and tyrosine) and generation of the oxidative species is slow
(i.e., hemin-hydrogen peroxide), MnTMPyP instead acts as an antioxidant engen-
dering a protective effect as a sacrificial substrate. Under more strongly oxidizing
conditions, such as hemin-ONOO, MnTMPyP again fails to convey any protection.
The observed toxic effect for MnTMPyP in in vitro cell culture could also reflect the
release of free Mn as a result of the rapid oxidative decomposition of this particular
porphyrin complex seen upon treatment with hemin and H2O2.
61
Cellular Assays and Stability Studies
In vitro toxicity experiments with MMn using Neuro-2A revealed that MMn displays
an IC50 of 95 mM after an 18 h incubation time at 37C, as inferred from a standard
MTT assay (Figure S40). MMn has been previously determined to be well tolerated
in vivo, as deduced from studies involving 2.5 mg kg1 daily injections in ALS G93A
mice.55 Notably, in these same studies, HPLC analysis of Mn texaphyrin-treatedmice
(end of study) revealed lower levels of nitrotyrosine in the spinal cord than in un-
treated controls. MMn-based nanoparticles have also been evaluated in vivo by sub-
jecting healthy female BABL/c mice (n = 5) to high-dose injections (10 mg kg1).42
Again, good tolerability was seen.
In vitro stability studies in the presence of ascorbate, albumin, zinc, copper, and cit-
ric acid revealed good stability at 37C over 24 h (Figure S41). In the presence of the
oxidative mixture composed of hemin and H2O2, MMn displayed increased stability
versus hemin and MnTMPyP when incubated at 37C (Figure S42). MMn, MnTMPyP,
and hemin all displayedmoderate stability when incubated with ONOO (2 equiv) at
37C for 0.5 h with 80%, 84%, and 71% of these complexes, respectively, after the
addition of excess NaAsc (Figure S43).
The cellular protective effect of MMn was demonstrated via MTT assays with Neuro-
2A cells. Previous studies have shown that the cytotoxic effects of Ab are dependent
upon the aggregate structure (i.e., fibril, oligomer, and aggregate).62,63 Oxidative
and nitrative modifications of the peptide alters its aggregation properties and
can enhance cytotoxic pathways.64–67 We thus sought to determine how partial
oxidation and nitration of Ab40, coupled with modification of the aggregated Ab40Chem 6, 1–22, March 12, 2020 15
Figure 9. Cellular (Neuro-2A) MTT Assay
Neuro-2A cell viability upon exposure to Ab40 and mixed oxidized-nitrated Ab40 (hemin-H2O2-
NaNO2) with and without MMn, MGd, and MnTMPyP. Reported values are the average with
standard deviation of three independent assays each tested four times. The Ab40 ‘‘NO2’’ mix is an
average of two independent assays each tested four times. *Two-sample t test on percent cell
viability (MTT assay) between the Ab40 ‘‘NO2’’ mix with and without MMn; p = 0.00016.
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Ab42, it is one of the predominant Ab species found within the AD brain. Ab40 also
displays a slower aggregation rate and lower toxicity than Ab42, allowing for
enhanced control in cell experiments. We assessed the protective effects of MMn
and MnTMPyP by incubating Ab40 for 3 h at 37C in the presence of a nitration
mixture containing hemin, H2O2, and NaNO2 in PBS. MGd was utilized as a negative
control because of its ability to propagate oxidative damage.19,23 We then stored
the reaction mixture at 4C overnight to allow the formation of additional toxic
fibrils35 before transferring it to wells containing Neuro-2A cells and subjecting it
to incubation for an additional 24 h. In comparison to the unmodified Ab40 not sub-
jected to the nitration conditions (90.4% G 2%), the mixed oxidized-nitrated Ab40
was more toxic, resulting in only 64.1% G 0.1% cell viability. In the presence of
MMn (30 mM), the neuroblastoma Neuro-2A cell viability was increased to
85.5% G 1.5%. MGd (30 mM) displayed cytotoxicity similar to that of the mixed
oxidized-nitrated Ab40 system, where only 58.25%G 13% cell viability was observed
(Figure 9). MnTMPyP (30 mM) also produced a lower level of cell viability (44.62%G
10%). On the basis of these experiments, we conclude that MMn provides a protec-
tive effect against the oxidative and nitrative modifications that are thought to yield
the neurotoxic fibril and oligomeric species that lead to cell death. In the event, the
incubation with MMn translates into improved cell viability.
Qualitative HPLC-MS analyses were carried out in an effort to correlate further the
level of Ab40 oxidation and the observed survival effects seen in Neuro-2A (Fig-
ure S44). A mixture of Ab40 (100 mM), hemin (15 mM), and H2O2 (1 mM) was incu-
bated with or without MMn (30 mM), MnTMPyP (30 mM), or MGd (30 mM) in PBS at
37C for 3 h. MMn conferred the greatest protective effect, yielding an approxi-
mately 1:1 ratio of oxidized (Ab40-[O] to native Ab40). This stands in contrast to
the sample containing MGd, where the resultant HPLC trace showed a 1.7:1 ratio
of Ab40-[O]/Ab40. Finally, MnTMPyP induced a high level of oxidative modification
with an approximately 3:1 ratio of Ab40-[O] to Ab40 being seen. Tandem mass
spectrometry (MS/MS) analysis proved consistent with oxidation occurring primar-
ily at His13-14 and Met35. When considered in conjunction with the N2 cell data,16 Chem 6, 1–22, March 12, 2020
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nitrative modification in the case of the Ab40 peptide. Previous studies have
demonstrated that variations in cell toxicity are correlated with the Ab40 aggrega-
tion state, meaning that they could be subject to potential modulation (i.e.,
enhanced or retarded toxicity) by porphyrinoid additives.30–32 MMn appears
particularly effective in this regard.Conclusions
In conclusion, we have demonstrated that metallotexaphyrins interact with Ab pep-
tides and aggregates and could hold promise for the MRI-based recognition of
amyloid aggregates. The first-generation water-soluble MMn that is the subject of
the present study also protects against oxidative and nitrative damage of small mol-
ecules and peptides and reduces Ab-mediated cell death. MMn was also shown to
permeate the cellular membrane and be taken up within C. elegans animal models
of AD. The present results thus serve to highlight the potential of MRI-active metal-
loantioxidants as potential treatment- and diagnostic-related modalities for use in
the diagnosis and management of neurodegenerative disease.EXPERIMENTAL PROCEDURES
Synthesis of Ab16 and Ab40
Ab peptides were prepared via Fmoc amino solid-phase peptide synthesis with a
Liberty Blue microwave peptide synthesizer. Preparative reverse-phase high-perfor-
mance liquid chromatography (RP-HPLC) purification of peptides was performed
with an Agilent Zorbax SB-C18 Prep HT column 21.2 3 250 mm. Analytical RP-
HPLC characterization of peptides was performed with an Agilent Zorbax column
4.6 3 250 mm. An Agilent Technologies 6530 Accurate Mass QT of LC/MS was
used for high-resolution mass spectra of purified peptides. Solvents used were
HPLC grade.Synthesis of MGd, MMn, and MLu
Motexafin gadolinium (gadolinium(III) texaphyrin [MGd]) was a gift from Pharmacy-
clics Inc., recently acquired by Abbvie. MLu and MMn were synthesized according
to literature protocols.53,68Cell-Uptake Studies
Neuro-2A cells were grown until confluent in T-75 flasks. MMn was added (100 mM)
and cells were incubated for 9 h, upon which cells were washed twice with PBS, incu-
bated with trypsin (13) for 2 min, diluted with supplemented Eagle’s minimal essen-
tial medium (EMEM), counted, and pelleted by centrifugation (3 min at 2,000 rpm).
After supernatant removal, the pellet was suspended and washed one more time
with PBS (5 mL), and the pellet was reformed by centrifugation (3 min at
2,000 rpm). The cell pellet was digested in concentrated nitric acid (100 mL) for
15 h at 60C and diluted with miliQ water to a final concentration of 2%HNO3 before
being analyzed by ICP-MS.C. elegans Culture
The C. elegans strains N2 and CL4176 were provided by CGC (nematodes shipped
on 35 mm diameter plates), which is funded by the NIH Office of Research Infrastruc-
ture Programs (P40-OD010440). C. elegans were grown and maintained as
described in ‘‘WormBook: The Online Review of C. elegans Biology’’ by Theresa
Stiernagle (https://www.ncbi.nlm.nih.gov/books/NBK19649/).Chem 6, 1–22, March 12, 2020 17
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After the C. elegans animals, N2 and CL4176, were received from the CGC (Uni-
versity of Minnesota) on petri dishes, agar matrix was cut in small chunks (0.5 3
0.5 cm) with a razor blade and transferred on nematode growth medium (NGM)
agar plates previously seeded with E. coli strain OP50 as a food source. NGM
plates were then placed at 16C in order to increase the population of
C. elegans before drug exposure and prevent significant plaque formation in the
CL4176 AD model. After 7 days, MMn was added to plates (1 mL per plate of a
solution at 100 mM), which were incubated at 25C for 48 h. The animals were
then transferred to Eppendorf tubes (previously weighted empty on an analytical
balance) with 1.5 mL of water. The tubes were put on ice for 5 min and centrifuged
(14,000 rpm for 1 min), and the supernatant was removed. The plate was washed
again with 1.5 mL of water and centrifuged again. The resulting pellets were
washed twice with 1 mL of DI water. C. elegans pellets were lyophilized over a
period of 15 h before being weighed (dry pellet weights obtained by lyophilization
were used to normalize the MRI and ICP-MS results).Preparation of Peroxynitrite
Three separate solutions of NaNO2 (0.6 M), HCl (0.68 M) with H2O2 (0.72 M), and
NaOH (3.6 M) were prepared and stored in the freezer at 20C for 30 min. The
solutions were transferred to an ice bath and allowed to sit for 30 min.
The NaNO2 solution was added to a 100 mL beaker placed in an ice bath and stirred
at >500 rpm. The HCl/H2O2 solution and NaOH solutions were added sequentially
such that the NaOH came immediately after the HCl/H2O2 solution. These solutions
must be added in sequence (i.e., one then the other) with as little time between the
two additions as possible. The best results were obtained by adding the two solu-
tions with a very small offset. The mixture turned yellow and was stirred in the ice
bath for 5 min. MnO2 was added portion-wise until gas evolution ceased. The
mixture was split into aliquots and centrifuged, and the peroxynitrite solution was
decanted with a glass pipette. The concentration could be calculated with lmax =
302 nm ε = 1,670 M1cm1. The best results were obtained by centrifugation in a
cold room at 4C. [peroxynitrite] = 72–86 mM.Serotonin-Hemin Reactivity Studies
Serotonin (1 mM), H2O2 (1 mM), hemin (15 mM), and sodium ascorbate (40 mM)
without and with MMn (120 mM) or MnTMPyP (120 mM) were incubated in PBS
(pH 7.4, 1.5 mL total volume) at 37C for 2 h in the dark. The resulting mixture was
passed through a reverse-phase tC18 SPE (Waters Sep-Pak, Waters) column contain-
ing 10 g of the C-18 substrate. The columnwas washed with 25mL of 5% acetonitrile:
H2O to separate the serotonin and 4,40-serotonin dimer from paramagnetic species.
The resulting solution was concentrated with a rotary evaporator. The mixture was
taken up in D2O (0.7 mL) and analyzed via
1H NMR spectroscopy. NMR spectro-
scopic yields were calculated by comparing the relative concentration of serotonin
to the 4,40-serotonin dimer. Note that additional washing of the column failed to
yield additional serotonin or the 4,40-serotonin dimer.Ab16 and Ab40 Reactivity Studies
Hemin Oxidative Reactivity Conditions
Hemin (15 mM) and H2O2 (1 mM) and Ab16 (300 mM) or Ab40 (100 and 200 mM) in PBS
(200 mL total volume) were incubated together at 37C. The resulting mixtures were
immediately subjected to HPLC-MS analysis. Vials were cooled to 4C inside the
HPLC-MS queue to prevent additional reactivity.18 Chem 6, 1–22, March 12, 2020
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Hemin (15 mM), NaNO2 (1 mM), H2O2 (1 mM), and Ab16 (300 mM) or Ab40 (100 and
200 mM) in PBS (200 mL total volume) were incubated together at 37C. The resulting
mixtures were immediately subjected to HPLC-MS analysis. Vials were cooled to 4C
inside the HPLC-MS queue to prevent additional reactivity.
Hemin-Peroxynitrite Nitrative Reactivity Conditions
Hemin (15 mM), peroxynitrite (1 mM), and Ab16 (300 mM) in PBS (200 mL total volume)
were incubated together at 37C. All compounds were added and then vortexed to
provide a homogenous mixture. Immediately after peroxynitrite was added, the
mixture was vortexed again and allowed to incubate at 37C for 30min. The resulting
mixtures were immediately subjected to HPLC-MS analysis. Vials were cooled to 4C
inside the HPLC-MS queue to prevent additional reactivity.Cell Culture
The neuroblastoma cell line Neuro-2A was bought from ATCC. Cells were grown in
EMEM containing 10% heat-inactivated fetal bovine serum (FBS) and antibiotics
(100 mg/mL streptomycin and 100 U/mL penicillin) at 37C under 5% CO2 atmo-
sphere. The cells were sub-cultured once every 4 to 5 days.Neuro-2A MTT Assay
Ab40 (90 mM) was incubated in PBS alone or in the presence of H2O2 (1 mM), hemin
(15 mM), and NaNO2 (1 mM) (referred to as nitration mixture) for 3 h at 37C followed
by 24 h at 4C. 250 mL of each of the solutions was transferred into each well contain-
ing about 50,000 Neuro-2A cells (plated 24 h earlier) in 250 mL of supplemented
EMEM without phenol red. After 24 h, the medium was removed and replaced
with 500 mL of fresh EMEM not containing FBS or phenol red. To this was added
200 mL of an MTT solution at 3 mg/mL in EMEM not containing phenol red or FBS.
After 4 h at 37C, the supernatant was removed and 200 mL of DMSO was added
to each well to dissolve the formazan purple crystals. Aliquots (50 mL) of each well
were transferred into a 96-well plate well, and the absorbance at 570 nm was read
with a plate reader (see description above).SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.chempr.
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